Literature DB >> 22412152

Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia.

Adèle C Green1, Peter Baade, Michael Coory, Joanne F Aitken, Mark Smithers.   

Abstract

PURPOSE: The 20-year survival rates are unknown for the majority of melanoma patients-those with thin melanomas. We determined 20-year survival rates of patients diagnosed with thin melanomas (≤ 1.00 mm) in the general population and also determined the main prognostic factors. PATIENTS AND METHODS: Available clinical and histologic data from the Queensland Cancer Registry were obtained for all patients diagnosed with a single thin invasive melanoma from 1982 to 2006 and matched against national death registration data. Melanoma-specific survival estimates to December 31, 2007, were assessed, and subgroup differences in prognosis were determined by fitting multivariate Cox proportional hazard models.
RESULTS: Among 26,736 people in the state of Queensland diagnosed with thin melanomas, the 20-year survival was 96%. The most influential determinants of prognosis were tumor thickness ≥ 0.75 mm (adjusted hazard ratio [HR], 4.33; 95% CI, 2.8 to 6.8 compared with tumors < 0.25 mm) and patient age at diagnosis older than 65 years (HR, 2.8; 95% CI, 1.8 to 4.5) compared with age younger than 25 years. Acral lentiginous and nodular tumors, male sex, tumor site on the scalp or neck, or tumor invasion of the entire papillary dermis each independently increased the risk of dying from thin invasive melanoma.
CONCLUSION: The outlook for patients with thin invasive melanoma is positive, although continued clinical vigilance is warranted for patients with nodular melanoma and those with the thickest tumors.

Entities:  

Mesh:

Year:  2012        PMID: 22412152     DOI: 10.1200/JCO.2011.38.8561

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  36 in total

Review 1.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

2.  Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications.

Authors:  Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry
Journal:  J Invest Dermatol       Date:  2016-06-25       Impact factor: 8.551

3.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 4.  Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?

Authors:  Oriol Yélamos; Pedram Gerami
Journal:  Melanoma Manag       Date:  2015-08-10

5.  Thin melanoma and late recurrences: it is never too thin and never too late.

Authors:  Antonio Giovanni Richetta; Ugo Bottoni; Giovanni Paolino; Rita Clerico; Carmen Cantisani; Marina Ambrifi; Paola Corsetti; Stefano Calvieri
Journal:  Med Oncol       Date:  2014-03-08       Impact factor: 3.064

6.  Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Authors:  Nancy E Thomas; Sharon N Edmiston; Audrey Alexander; Pamela A Groben; Eloise Parrish; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Lynn From; Klaus J Busam; Honglin Hao; Irene Orlow; Peter A Kanetsky; Li Luo; Anne S Reiner; Susan Paine; Jill S Frank; Jennifer I Bramson; Lorraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Anne E Cust; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

7.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia.

Authors:  David C Whiteman; Peter D Baade; Catherine M Olsen
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

8.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

9.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

10.  Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Authors:  Michael A Marchetti; Daniel G Coit; Stephen W Dusza; Ashley Yu; LaToya McLean; Yinin Hu; Japbani K Nanda; Konstantina Matsoukas; Silvia E Mancebo; Edmund K Bartlett
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.